Teva Pharmaceutical Industries Ltd. $TEVA Holdings Decreased by Tejara Capital Ltd

Tejara Capital Ltd lessened its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 56.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 78,500 shares of the company’s stock after selling 102,300 shares during the period. Tejara Capital Ltd’s holdings in Teva Pharmaceutical Industries were worth $1,316,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Ion Asset Management Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 6.5% in the 1st quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock worth $599,945,000 after acquiring an additional 2,383,500 shares during the period. Phoenix Financial Ltd. lifted its position in Teva Pharmaceutical Industries by 31.7% in the second quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock worth $632,882,000 after purchasing an additional 9,094,372 shares during the period. Harel Insurance Investments & Financial Services Ltd. lifted its position in Teva Pharmaceutical Industries by 51.4% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock worth $559,622,000 after purchasing an additional 11,334,780 shares during the period. Menora Mivtachim Holdings LTD. boosted its stake in Teva Pharmaceutical Industries by 2.8% during the 1st quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company’s stock valued at $448,640,000 after purchasing an additional 808,074 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Teva Pharmaceutical Industries by 8.9% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,685,422 shares of the company’s stock valued at $480,768,000 after purchasing an additional 2,350,000 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total value of $4,822,000.00. Following the completion of the sale, the director directly owned 495,000 shares in the company, valued at $11,934,450. The trade was a 28.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.49% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Trading Up 5.3%

Shares of NYSE TEVA opened at $26.32 on Friday. The business has a fifty day simple moving average of $21.43 and a 200-day simple moving average of $18.74. The company has a market cap of $30.19 billion, a price-to-earnings ratio of -164.51, a P/E/G ratio of 1.11 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $26.45. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $25.86.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.